BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 7.9% – Here’s What Happened

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s stock price dropped 7.9% during mid-day trading on Friday . The company traded as low as $8.45 and last traded at $8.3720. 95,326 shares were traded during trading, a decline of 74% from the average daily volume of 371,229 shares. The stock had previously closed at $9.09.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. Canaccord Genuity Group began coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price objective for the company. Oppenheimer started coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $27.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.80.

BridgeBio Oncology Therapeutics Stock Down 7.1%

The firm has a market capitalization of $676.61 million, a PE ratio of -4.10 and a beta of 0.39. The stock’s 50-day simple moving average is $8.11.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. As a group, equities research analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. CIBC Private Wealth Group LLC acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $63,000. Persistent Asset Partners Ltd acquired a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $107,000. Squarepoint Ops LLC acquired a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $144,000. Quadrature Capital Ltd bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at $162,000. Finally, BIT Capital GmbH bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at $313,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.